The Presence of a BRCA Mutation in Patients with Breast Cancer
Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, comments on the presence of a BRCA mutation in her patients.
Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, comments on the presence of a BRCA mutation in her patients.
Clinical Pearls
While a BRCA mutation used to be considered a negative prognostic factor in patients with breast cancer, it can now be considered a good thing, Daugherty says. Patients with the BRCA mutation are more amenable to platinum therapy and are eligible for PARP trials. It remains important for nurses and doctors to inform patients about new knowledge concerning BRCA.
- While the presence of a BRCA mutation used to be considered negative, it can now be considered positive, Daugherty says
- Patients with BRCA mutations are more amenable to platinum therapy and are eligible for PARP trials
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
